Tags

Type your tag names separated by a space and hit enter

Carbamazepine in the treatment of neuroleptic malignant syndrome.
Biol Psychiatry. 1998 Feb 15; 43(4):303-5.BP

Abstract

BACKGROUND

Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse effect to neuroleptic drugs.

METHODS

We report on 2 cases where NMS dramatically improved with carbamazepine. Incidental removal and reapplication of carbamazepine attests to its effectiveness for this condition.

RESULTS

A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine. Her condition dramatically improved in 8 hours after she was administered carbamazepine. Since carbamazepine was discontinued, NMS recurred in 10 hours and remitted anew within less than 24 hours after reintroduction. A 31-year-old woman experiencing a schizoaffective disorder displayed NMS with aphenothiazine and a butyrophenone. NMS completely resolved within 8 hours after she was administered carbamazepine. NMS recurred within 12 hours after carbamazepine discontinuation.

CONCLUSIONS

These data thus account for a cause-effect relationship between carbamazepine administration and NMS relief, and argue against the neuroleptic withdrawal to be responsible by itself for NMS relief.

Links

Publisher Full Text

Authors+Show Affiliations

Thomas P
Department of Psychiatry, School of Medicine, Centre Hospitalier Regional et Universitaire, University of Lille, France.
Maron M
No affiliation info available
Rascle C
No affiliation info available
Cottencin O
No affiliation info available
Vaiva G
No affiliation info available
Goudemand M
No affiliation info available

MeSH

AdultAnticonvulsantsAntipsychotic AgentsCarbamazepineDepressive DisorderFemaleHaloperidolHumansNeuroleptic Malignant SyndromePhenothiazines

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

9513741

Citation

Thomas, P, et al. "Carbamazepine in the Treatment of Neuroleptic Malignant Syndrome." Biological Psychiatry, vol. 43, no. 4, 1998, pp. 303-5.
Thomas P, Maron M, Rascle C, et al. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry. 1998;43(4):303-5.
Thomas, P., Maron, M., Rascle, C., Cottencin, O., Vaiva, G., & Goudemand, M. (1998). Carbamazepine in the treatment of neuroleptic malignant syndrome. Biological Psychiatry, 43(4), 303-5.
Thomas P, et al. Carbamazepine in the Treatment of Neuroleptic Malignant Syndrome. Biol Psychiatry. 1998 Feb 15;43(4):303-5. PubMed PMID: 9513741.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Carbamazepine in the treatment of neuroleptic malignant syndrome. AU - Thomas,P, AU - Maron,M, AU - Rascle,C, AU - Cottencin,O, AU - Vaiva,G, AU - Goudemand,M, PY - 1998/3/26/pubmed PY - 1998/3/26/medline PY - 1998/3/26/entrez SP - 303 EP - 5 JF - Biological psychiatry JO - Biol Psychiatry VL - 43 IS - 4 N2 - BACKGROUND: Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse effect to neuroleptic drugs. METHODS: We report on 2 cases where NMS dramatically improved with carbamazepine. Incidental removal and reapplication of carbamazepine attests to its effectiveness for this condition. RESULTS: A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine. Her condition dramatically improved in 8 hours after she was administered carbamazepine. Since carbamazepine was discontinued, NMS recurred in 10 hours and remitted anew within less than 24 hours after reintroduction. A 31-year-old woman experiencing a schizoaffective disorder displayed NMS with aphenothiazine and a butyrophenone. NMS completely resolved within 8 hours after she was administered carbamazepine. NMS recurred within 12 hours after carbamazepine discontinuation. CONCLUSIONS: These data thus account for a cause-effect relationship between carbamazepine administration and NMS relief, and argue against the neuroleptic withdrawal to be responsible by itself for NMS relief. SN - 0006-3223 UR - https://www.unboundmedicine.com/medline/citation/9513741/Carbamazepine_in_the_treatment_of_neuroleptic_malignant_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-3223(97)00450-2 DB - PRIME DP - Unbound Medicine ER -